Alanyl-glutamine supplementation for Clostridioides difficile infection treatment (ACT): a double-blind randomised controlled trial study protocol.
Cirle A Warren, Jae Hyun Shin, Ekta N Bansal...
https://pubmed.ncbi.nlm.nih.gov/37474181/Actively Recruiting
Led by University of Virginia · Updated on 2024-10-26
260
Participants Needed
2
Research Sites
25 weeks
Total Duration
Researchers are evaluating the use of oral alanyl-glutamine AQ supplementation alongside standard therapy to treat Clostridioides difficile infection CDI in adults aged 18 and older. This Phase II, randomized, double-blind, placebo-controlled trial aims to determine the optimal dose and safety of AQ given in doses of 0, 4, 24, or 44 grams daily for 10 days. The study hypothesizes that AQ may reduce CDI recurrence and mortality while improving inflammatory markers and intestinal microbiota function. Participants are randomly assigned to one of four groups receiving AQ at 4, 24, or 44 grams or a placebo, administered once daily orally or through a feeding tube if needed. The treatment lasts 10 days and is given alongside standard antibiotics such as oral vancomycin or fidaxomicin. The trial uses block randomization to maintain balance over the enrollment period and follows participants daily during treatment and weekly for 60 days afterward to monitor for recurrence and survival. During the study, researchers collect blood, urine, and stool samples at the start, after 10 days, and at 70 days to analyze inflammation and microbial changes. Participants may attend in-person or virtual visits, with options for sample shipment if needed. Safety is closely monitored throughout treatment and follow-up. The main outcome measured is the number of participants with recurrent CDI within 60 days post-treatment, with mortality as a secondary outcome. The total participation period covers treatment and 60 days of follow-up.
CONDITIONS
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Virginia
Lead Sponsor
Carilion Clinic
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | AQ + standard therapy | Placebo + standard therapy | Standard care (guideline‑based) |
|---|---|---|---|
| What it is | Oral alanyl‑glutamine added to standard oral vancomycin or fidaxomicin therapy at doses of 4 g, 24 g, or 44 g | Placebo (0 g AQ) added to standard oral vancomycin or fidaxomicin therapy | Standard guideline‑recommended oral therapy for CDI (e.g., fidaxomicin or vancomycin) without investigational supplementation |
| Role in trial | Investigational arms testing AQ supplementation at multiple doses | Control arm receiving placebo added to standard therapy | Contextual representation of how CDI is treated outside the trial |
| Primary use | To evaluate whether AQ supplementation reduces CDI recurrence or mortality when added to standard therapy | Control to compare recurrence and mortality outcomes without AQ | Current antibiotic‑based treatment used to manage CDI according to guidelines |
| How it is given or performed | Once‑daily oral AQ supplementation (4 g, 24 g, or 44 g) for 10 days alongside oral antibiotic therapy | Once‑daily oral placebo (0 g AQ) for 10 days alongside oral antibiotic therapy | Oral fidaxomicin or vancomycin per guideline‑recommended dosing regimens |
| Evidence status | Efficacy and safety are being investigated; outcomes include recurrence and mortality within 60 days | Provides baseline for assessing effect of AQ supplementation on recurrence and mortality | Well‑established guidelines show fidaxomicin (and vancomycin when needed) reduce recurrence when used appropriately |
| Important risks | Safety profile under study; risk evidence not yet established | Safety profile under study; placebo expected to carry minimal risk | Oral fidaxomicin and vancomycin are generally well tolerated per guidelines |
| Important limitations | Investigational supplement; efficacy and safety data pending | Only controls for supplementation effect; not representative of standalone therapy outcome | Guideline‑based care may not match investigational dosing context for AQ evaluation |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or virtual)
Duration - 10 days
Participants receive daily oral or enteral supplementation with alanyl-glutamine or placebo along with standard treatment for Clostridioides difficile infection.
Daily visits for adverse event monitoring during treatment
Duration - 60 days post-treatment
Participants are followed weekly for up to 60 days post-treatment to monitor for recurrence of infection and survival.
Weekly visits for up to 60 days post-treatment
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Cirle A Warren, Jae Hyun Shin, Ekta N Bansal...
https://pubmed.ncbi.nlm.nih.gov/37474181/University of Virginia
Lead Sponsor
Carilion Clinic
Collaborating Sponsor